Core Viewpoint - The company has received regulatory approvals for two eye drop products, PAN-90806 for wet age-related macular degeneration (wAMD) and epinastine hydrochloride for allergic conjunctivitis, indicating significant advancements in its product pipeline and potential market impact [1][2]. Group 1: PAN-90806 Development - The National Medical Products Administration (NMPA) approved the clinical trial application for PAN-90806 on November 18, 2025, aimed at treating wAMD [1]. - PAN-90806 is a novel anti-VEGF eye drop formulation that offers a less invasive treatment option, potentially reducing the frequency of intravitreal injections associated with mainstream therapies [1]. - The anticipated benefits of PAN-90806 include improved patient comfort, adherence, and convenience, which may help slow disease progression and reduce treatment interruptions [1]. Group 2: Market Potential for wAMD - wAMD is a leading cause of vision loss and blindness among individuals over 50 in China and globally [1]. - The market for wAMD drugs in China is projected to grow from $241.5 million in 2019 to approximately $3.5 billion by 2030, with a compound annual growth rate (CAGR) of 27.5% [1]. Group 3: Epinastine Hydrochloride Approval - The company announced the NMPA approval for epinastine hydrochloride eye drops for allergic conjunctivitis on November 19, 2025 [1]. - Epinastine hydrochloride acts as a dual mechanism treatment, providing antihistamine effects and stabilizing mast cells, making it a first-line therapy for allergic conjunctivitis in China [2].

Group 1 - The article discusses the challenges faced by patients with allergic conjunctivitis during autumn, highlighting symptoms such as itching, redness, and tearing, which significantly impact quality of life [1] - Various types of eye medications are categorized, including antihistamines like Levocabastine and Emedastine, and dual-action drugs that stabilize mast cells and provide antihistamine effects, such as Nedocromil and Olopatadine [1] - Vasoconstrictor eye drops, such as Oxymetazoline and Naphazoline, are mentioned for their role in reducing redness and irritation by constricting blood vessels in the conjunctiva [1] Group 2 - Corticosteroid eye drops, including Dexamethasone, Fluorometholone, and Prednisolone, are noted for their effectiveness in treating severe or chronic allergic conjunctivitis and inflammation [2] - The article emphasizes the importance of monitoring for potential side effects like eye infections, increased intraocular pressure, and cataracts when using corticosteroid eye drops [2] - It is recommended that patients with concurrent allergic conditions consult healthcare professionals for appropriate oral or injectable medications and to identify allergens to avoid [3]